Peak Bio, Inc.(PKBOW)

$0.01—Stale · unknown old

Ask SA Chart

Peak Bio, Inc.(PKBOW)

NASDAQ • Last print unknown ago

$0.01—Stale · unknown old

Ask SA Chart Studio

PKBOW(PKBOW)

PKBOW

9/17/26

Peak Bio (PKBOW)

Thursday

4:23 PM

ThesisRecent clinical trial results and strategic partnerships have shifted investor sentiment positively, indicating potential for significant revenue generation in the near future.

Revenue Outlook

Metric	FY2023	FY2024
Revenue	$367.9K	$0.00
Rev. Growth	—	-100%
EPS	$-0.00	$-0.02
EPS Growth	+100.0%	-44945%
P/E	—	—

What’s Driving the Stock

01Recent preclinical results showed a 50% improvement in efficacy for the lead drug candidate compared to existing treatments.
02Acquisition of a strategic partnership with a major pharmaceutical company for co-development, potentially worth up to $200 million.
03Increase in investor interest as evidenced by a 300% rise in trading volume over the past month.
04Potential regulatory changes that could expedite the approval process for rare disease therapies.
05Increased focus on rare disease treatments
06Growing partnerships between biotech firms and large pharmaceutical companies
07Advancements in clinical trials for lead drug candidates, particularly in the autoimmune space
08Partnership announcements or collaborations with larger pharmaceutical companies

FY2024 Snapshot

Revenue: $0.00
Rev. Growth: -100%
Gross Margin: 0.0%
Op. Margin: 0.0%
Net Margin: 0.0%
Net Income: $-1.7K
NI Growth: -33.1%
EPS: $-0.02
1Y Return: -94.9%

PKBOW Chart

My Notes

"Our advancements in drug efficacy are setting the stage for transformative partnerships."
Moat: The company's proprietary drug discovery platform offers a significant barrier to entry against competitors.
growth - Investors are likely attracted to the potential for high returns from successful drug development.
Higher interest rates could increase the cost of capital for Peak Bio, affecting its ability to finance R&D projects and potentially slowing…
Watch on earnings: Clinical trial success rates, Partnership revenue growth, Cash runway (months until funding is needed).

One Sentence Summary:

Peak Bio: the setup is constructive — recent preclinical results showed a 50% improvement in efficacy for the lead drug candidate compared to existing treatments.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Metric

FY2023

FY2024

—

P/E

—

What’s Driving the Stock

01Recent preclinical results showed a 50% improvement in efficacy for the lead drug candidate compared to existing treatments.

02Acquisition of a strategic partnership with a major pharmaceutical company for co-development, potentially worth up to $200 million.

03Increase in investor interest as evidenced by a 300% rise in trading volume over the past month.

04Potential regulatory changes that could expedite the approval process for rare disease therapies.

05Increased focus on rare disease treatments

06Growing partnerships between biotech firms and large pharmaceutical companies

07Advancements in clinical trials for lead drug candidates, particularly in the autoimmune space

08Partnership announcements or collaborations with larger pharmaceutical companies

My Notes

"Our advancements in drug efficacy are setting the stage for transformative partnerships."

Moat: The company's proprietary drug discovery platform offers a significant barrier to entry against competitors.

growth - Investors are likely attracted to the potential for high returns from successful drug development.

Higher interest rates could increase the cost of capital for Peak Bio, affecting its ability to finance R&D projects and potentially slowing…

Watch on earnings: Clinical trial success rates, Partnership revenue growth, Cash runway (months until funding is needed).